Protocolnummer: NL 48639.031.14

REPOSIT (gesloten voor inclusie)

A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction with Positron Emission Tomography and Tumor Characteristics. REPOSIT.
 

Ziekenhuizen

  • AmsterdamUMC
  • Antoni van Leeuwenhoek (NKI) ziekenhuis Amsterdam
  • Erasmus Medisch Centrum Rotterdam
  • Isala Zwolle
  • Leids Universitair Medisch Centrum
  • Maastricht UMC+
  • Maxima Medisch Centrum Eindhoven
  • Medisch Spectrum Twente Enschede
  • RadboudUMC Nijmegen
  • Universitair Medisch Centrum Groningen
  • Universitair Medisch Centrum Utrecht

Behandeling

Vemurafenib (960mg BID) and Cobimetinib (60mg QD)

Belangrijkste in/exclusiecriteria

In: Patient with unresectable stage IIIc or stage IV confirmed BRAF mutation-positive metastatic melanoma, no prior RAF or MEK pathway inhibitor treatment, evaluable disease by CT and PET, ECOG performance status of 0-1. Ex: symptomatic brain metastases, impaired cardiac function, retinal disease.

Contactpersoon

Prof. J.B.A.G. Haanen / Dr. A.J.M. van den Eertwegh